Drifts in N-Linked Glycosylation Result in ADCC Potency Variation of Perjeta® from August 2020 to October 2021 in China

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2022 May 10

PMID 35535043

Authors

Bing Yao

Di Zhang

Weirong Cao

Gaoqiang Yang

Wenbin Li

Xiwu Hui

Pingkai Ouyang

Guoguang Chen

Boning Liu

Affiliations

Soon will be listed here.

Abstract

The proposed biosimilar candidate needs to demonstrate biosimilarity with reference products, and the quality target product profile and biosimilarity assessment criteria are prerequisite, which should be based on extensive characterization of the reference products. In this study, 13 lots of China-sourced pertuzumab (trademark: Perjeta®), with an expiration date from 2020 to 2021, were comprehensively characterized. Despite the consistency of purity, drifts in N-glycan profile were observed, which resulted in the variation of antibody-dependent cellular cytotoxicity (ADCC) activity. In detail, four parametric curves of ADCC activity of the reference product were unparalleled, and the maximum response value was highly related to the content of %afucose than half-maximal effective concentration (EC). As ADCC is a potential critical quality attribute of Perjeta®, the glycosylation of Perjeta® and its biosimilars should be tightly monitored and controlled.

References

Huang S, Li F, Liu H, Ye P, Fan X, Yuan X . Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody. MAbs. 2018; 10(6):864-875. PMC: 6152455. DOI: 10.1080/19420862.2018.1486946. View

Thomann M, Reckermann K, Reusch D, Prasser J, Tejada M . Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Mol Immunol. 2016; 73:69-75. DOI: 10.1016/j.molimm.2016.03.002. View

Wada R, Matsui M, Kawasaki N . Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms. MAbs. 2018; 11(2):350-372. PMC: 6380427. DOI: 10.1080/19420862.2018.1551044. View

Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R . Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng. 2004; 87(5):614-22. DOI: 10.1002/bit.20151. View

Gottschalk P, Dunn J . Measuring parallelism, linearity, and relative potency in bioassay and immunoassay data. J Biopharm Stat. 2005; 15(3):437-63. DOI: 10.1081/BIP-200056532. View

Kim S, Song J, Park S, Ham S, Paek K, Kang M . Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar. MAbs. 2017; 9(4):704-714. PMC: 5419076. DOI: 10.1080/19420862.2017.1305530. View

Cerutti M, Pesce A, Bes C, Seigelchifer M . Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar. BioDrugs. 2019; 33(3):307-319. DOI: 10.1007/s40259-019-00349-2. View

Hutterer K, Polozova A, Kuhns S, McBride H, Cao X, Liu J . Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab. BioDrugs. 2019; 33(3):321-333. PMC: 6533217. DOI: 10.1007/s40259-019-00350-9. View

Pivot X, Pegram M, Cortes J, Luftner D, Lyman G, Curigliano G . Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. Eur J Cancer. 2019; 120:1-9. DOI: 10.1016/j.ejca.2019.07.015. View

10.

Shields R, Lai J, Keck R, OConnell L, Hong K, Meng Y . Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002; 277(30):26733-40. DOI: 10.1074/jbc.M202069200. View

11.

Zhang T, Zhang J, Hewitt D, Tran B, Gao X, Qiu Z . Identification and characterization of buried unpaired cysteines in a recombinant monoclonal IgG1 antibody. Anal Chem. 2012; 84(16):7112-23. DOI: 10.1021/ac301426h. View

12.

Upton R, Bell L, Guy C, Caldwell P, Estdale S, Barran P . Orthogonal Assessment of Biotherapeutic Glycosylation: A Case Study Correlating N-Glycan Core Afucosylation of Herceptin with Mechanism of Action. Anal Chem. 2016; 88(20):10259-10265. DOI: 10.1021/acs.analchem.6b02994. View

13.

Xie L, Zhang E, Xu Y, Gao W, Wang L, Xie M . Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology. BioDrugs. 2020; 34(3):363-379. PMC: 7211197. DOI: 10.1007/s40259-020-00407-0. View

14.

Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S . Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells. 2011; 16(11):1071-80. PMC: 3258418. DOI: 10.1111/j.1365-2443.2011.01552.x. View

15.

Kiyoshi M, Caaveiro J, Tada M, Tamura H, Tanaka T, Terao Y . Assessing the Heterogeneity of the Fc-Glycan of a Therapeutic Antibody Using an engineered FcγReceptor IIIa-Immobilized Column. Sci Rep. 2018; 8(1):3955. PMC: 5834517. DOI: 10.1038/s41598-018-22199-8. View

16.

Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R . Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011; 29(4):310-2. DOI: 10.1038/nbt.1839. View

17.

Chung S, Lin Y, Reed C, Ng C, Cheng Z, Malavasi F . Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells. J Immunol Methods. 2014; 407:63-75. DOI: 10.1016/j.jim.2014.03.021. View

18.

Lee J, Paek K, Moon J, Ham S, Song J, Kim S . Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment. BioDrugs. 2019; 33(4):411-422. PMC: 6647423. DOI: 10.1007/s40259-019-00362-5. View